Nasdaq · Healthcare

ENANTA PHARMACEUTICALS INC (ENTA)

As-reported financials and recent SEC filings for ENANTA PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$65.3M

Net income

$-81.9M

Net margin

-125.4%

Diluted EPS

$-3.84

ROE

-126.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$65.3M	$67.6M	$79.2M	$86.2M	$97.1M
Gross profit	—	—	—	—	—
Operating income	$-85.3M	$-121.7M	$-137.2M	$-123.8M	$-109.6M
Net income	$-81.9M	$-116.0M	$-133.8M	$-121.8M	$-79.0M
Diluted EPS	$-3.84	$-5.48	$-6.38	$-5.91	$-3.92

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-02

424B52026-07-02

8-K2026-06-23

8-K2026-06-18

S-82026-05-13

10-Q2026-05-13

8-K2026-05-11

8-K2026-03-26

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ENTA

Search ENANTA PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.